<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37758654</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-3624</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Open heart</Title><ISOAbbreviation>Open Heart</ISOAbbreviation></Journal><ArticleTitle>Risk factors, outcomes and healthcare utilisation in individuals with multimorbidity including heart failure, chronic kidney disease and type 2 diabetes mellitus: a national electronic health record study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e002332</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/openhrt-2023-002332</ELocationID><Abstract><AbstractText Label="BACKGROUND">Heart failure (HF), type 2 diabetes (T2D) and chronic kidney disease (CKD) commonly coexist. We studied characteristics, prognosis and healthcare utilisation of individuals with two of these conditions.</AbstractText><AbstractText Label="METHODS">We performed a retrospective, population-based linked electronic health records study from 1998 to 2020 in England to identify individuals diagnosed with two of: HF, T2D or CKD. We described cohort characteristics at time of second diagnosis and estimated risk of developing the third condition and mortality using Kaplan-Meier and Cox regression models. We also estimated rates of healthcare utilisation in primary care and hospital settings in follow-up.</AbstractText><AbstractText Label="FINDINGS">We identified cohorts of 64&#x2009;226 with CKD and HF, 82&#x2009;431 with CKD and T2D, and 13&#x2009;872 with HF and T2D. Compared with CKD and T2D, those with CKD and HF and HF and T2D had more severe risk factor profile. At 5 years, incidence of the third condition and all-cause mortality occurred in 37% (95% CI: 35.9%, 38.1%%) and 31.3% (30.4%, 32.3%) in HF+T2D, 8.7% (8.4%, 9.0%) and 51.6% (51.1%, 52.1%) in HF+CKD, and 6.8% (6.6%, 7.0%) and 17.9% (17.6%, 18.2%) in CKD+T2D, respectively. In each of the three multimorbid groups, the order of the first two diagnoses was also associated with prognosis. In multivariable analyses, we identified risk factors for developing the third condition and mortality, such as age, sex, medical history and the order of disease diagnosis. Inpatient and outpatient healthcare utilisation rates were highest in CKD and HF, and lowest in CKD and T2D.</AbstractText><AbstractText Label="INTERPRETATION">HF, CKD and T2D carry significant mortality and healthcare burden in combination. Compared with other disease pairs, individuals with CKD and HF had the most severe risk factor profile, prognosis and healthcare utilisation. Service planning, policy and prevention must take into account and monitor data across conditions.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pasea</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dashtban</LastName><ForeName>Ashkan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mizani</LastName><ForeName>Mehrdad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhuva</LastName><ForeName>Anish</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7532-7815</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Barts Heart Centre, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiovascular Sciences, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Tamsin</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Real World Evidence, AstraZeneca, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mamza</LastName><ForeName>Jil Billy</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Real World Evidence, AstraZeneca, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banerjee</LastName><ForeName>Amitava</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8741-3411</Identifier><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK ami.banerjee@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Barts Heart Centre, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Open Heart</MedlineTA><NlmUniqueID>101631219</NlmUniqueID><ISSNLinking>2053-3624</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076322" MajorTopicYN="N">Multimorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051436" MajorTopicYN="Y">Renal Insufficiency, Chronic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">electronic health records</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">quality of health care</Keyword></KeywordList><CoiStatement>Competing interests: JBM and TM are employed by AstraZeneca UK, a biopharmaceutical company. AB is supported by research funding from the National Institute for Health Research (NIHR), British Medical Association, AstraZeneca, the European Union, UK Research and Innovation, and Trustee of the South Asian Health Foundation and Long Covid SOS. Other authors report no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>28</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>27</Day><Hour>22</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37758654</ArticleId><ArticleId IdType="pmc">PMC10537985</ArticleId><ArticleId IdType="doi">10.1136/openhrt-2023-002332</ArticleId><ArticleId IdType="pii">openhrt-2023-002332</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cassell A, Edwards D, Harshfield A, et al. . The epidemiology of Multimorbidity in primary care: A retrospective cohort study. Br J Gen Pract 2018;68:e245&#x2013;51. 10.3399/bjgp18X695465</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/bjgp18X695465</ArticleId><ArticleId IdType="pmc">PMC5863678</ArticleId><ArticleId IdType="pubmed">29530918</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingston A, Robinson L, Booth H, et al. . Projections of multi-morbidity in the older population in England to 2035: estimates from the population ageing and care simulation (Pacsim) model. Age Ageing 2018;47:374&#x2013;80. 10.1093/ageing/afx201</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afx201</ArticleId><ArticleId IdType="pmc">PMC5920286</ArticleId><ArticleId IdType="pubmed">29370339</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofori-Asenso R, Chin KL, Curtis AJ, et al. . Recent patterns of Multimorbidity among older adults in high-income countries. Popul Health Manag 2019;22:127&#x2013;37. 10.1089/pop.2018.0069</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/pop.2018.0069</ArticleId><ArticleId IdType="pubmed">30096023</ArticleId></ArticleIdList></Reference><Reference><Citation>Muth C, Blom JW, Smith SM, et al. . Evidence supporting the best clinical management of patients with Multimorbidity and Polypharmacy: a systematic guideline review and expert consensus. J Intern Med 2019;285:272&#x2013;88. 10.1111/joim.12842</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.12842</ArticleId><ArticleId IdType="pubmed">30357955</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos T, Allen C, Arora M, et al. . Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990&#x2013;2015: a systematic analysis for the global burden of disease study 2015. The Lancet 2016;388:1545&#x2013;602. 10.1016/S0140-6736(16)31678-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)31678-6</ArticleId><ArticleId IdType="pmc">PMC5055577</ArticleId><ArticleId IdType="pubmed">27733282</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Mamza JB, Morris T, et al. . Lifetime risk of cardiovascular-renal disease in type 2 diabetes: a population-based study in 473,399 individuals. BMC Med 2022;20:63. 10.1186/s12916-022-02234-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02234-2</ArticleId><ArticleId IdType="pmc">PMC8822817</ArticleId><ArticleId IdType="pubmed">35130878</ArticleId></ArticleIdList></Reference><Reference><Citation>Birkeland KI, Bodegard J, Eriksson JW, et al. . Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. Diabetes Obes Metab 2020;22:1607&#x2013;18. 10.1111/dom.14074</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14074</ArticleId><ArticleId IdType="pmc">PMC7496468</ArticleId><ArticleId IdType="pubmed">32363737</ArticleId></ArticleIdList></Reference><Reference><Citation>Norhammar A, Bodegard J, Eriksson JW, et al. . Cost of Healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries. Diabetes Obes Metab 2022;24:1277&#x2013;87. 10.1111/dom.14698</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14698</ArticleId><ArticleId IdType="pmc">PMC9321691</ArticleId><ArticleId IdType="pubmed">35322567</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson L, Vieira R, Butler J, et al. . Identifying Multimorbidity clusters in an Unselected population of hospitalised patients. Sci Rep 2022;12:5134. 10.1038/s41598-022-08690-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-08690-3</ArticleId><ArticleId IdType="pmc">PMC8948299</ArticleId><ArticleId IdType="pubmed">35332197</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadam UT, Uttley J, Jones PW, et al. . Chronic disease Multimorbidity transitions across Healthcare interfaces and associated costs: A clinical-linkage database study. BMJ Open 2013;3:e003109. 10.1136/bmjopen-2013-003109</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2013-003109</ArticleId><ArticleId IdType="pmc">PMC3717459</ArticleId><ArticleId IdType="pubmed">23872294</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangaswami J, Tuttle K, Vaduganathan M. Cardio-renal-metabolic care models: toward achieving effective Interdisciplinary care. Circ Cardiovasc Qual Outcomes 2020;13:e007264. 10.1161/CIRCOUTCOMES.120.007264</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.120.007264</ArticleId><ArticleId IdType="pmc">PMC7673632</ArticleId><ArticleId IdType="pubmed">33176463</ArticleId></ArticleIdList></Reference><Reference><Citation>Giugliano D, Longo M, Scappaticcio L, et al. . SGLT-2 inhibitors and Cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 Cvots. Cardiovasc Diabetol 2021;20:236. 10.1186/s12933-021-01430-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01430-3</ArticleId><ArticleId IdType="pmc">PMC8680308</ArticleId><ArticleId IdType="pubmed">34915880</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoku Y, Takemoto M, Mito T, et al. . Impact of annual cardiovascular screening tests in patients with type 2 diabetes mellitus without previous histories of cardiovascular disease: four-year clinical outcomes. Intern Med 2021;60:2725&#x2013;32. 10.2169/internalmedicine.6893-20</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.6893-20</ArticleId><ArticleId IdType="pmc">PMC8479217</ArticleId><ArticleId IdType="pubmed">33716290</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett E, Gallagher AM, Bhaskaran K, et al. . Data resource profile: clinical practice research Datalink (CPRD). Int J Epidemiol 2015;44:827&#x2013;36. 10.1093/ije/dyv098</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyv098</ArticleId><ArticleId IdType="pmc">PMC4521131</ArticleId><ArticleId IdType="pubmed">26050254</ArticleId></ArticleIdList></Reference><Reference><Citation>Denaxas S, Gonzalez-Izquierdo A, Direk K, et al. . UK Phenomics platform for developing and validating electronic health record phenotypes: CALIBER. J Am Med Inform Assoc 2019;26:1545&#x2013;59. 10.1093/jamia/ocz105</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocz105</ArticleId><ArticleId IdType="pmc">PMC6857510</ArticleId><ArticleId IdType="pubmed">31329239</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation 2016;133:601&#x2013;9. 10.1161/CIRCULATIONAHA.115.017719</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.115.017719</ArticleId><ArticleId IdType="pmc">PMC4741409</ArticleId><ArticleId IdType="pubmed">26858290</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimbudzi E, Lo C, Ranasinha S, et al. . Health-related quality of life among patients with comorbid diabetes and kidney disease attending a Codesigned integrated model of care: a longitudinal study. BMJ Open Diabetes Res Care 2020;8:e000842. 10.1136/bmjdrc-2019-000842</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjdrc-2019-000842</ArticleId><ArticleId IdType="pmc">PMC6954749</ArticleId><ArticleId IdType="pubmed">31958294</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan BM, Sutherland SE, Tilkemeier PL, et al. . A cluster-based approach for integrating clinical management of Medicare beneficiaries with multiple chronic conditions. PLoS One 2019;14:e0217696. 10.1371/journal.pone.0217696</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0217696</ArticleId><ArticleId IdType="pmc">PMC6584004</ArticleId><ArticleId IdType="pubmed">31216301</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols GA, Ustyugova A, D&#xe9;ruaz-Luyet A, et al. . Health care costs by type of expenditure across eGFR stages among patients with and without diabetes, cardiovascular disease, and heart failure. J Am Soc Nephrol 2020;31:1594&#x2013;601. 10.1681/ASN.2019121308</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2019121308</ArticleId><ArticleId IdType="pmc">PMC7350988</ArticleId><ArticleId IdType="pubmed">32487562</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothwell PM, Coull AJ, Silver LE, et al. . Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford vascular study). Lancet 2005;366:1773&#x2013;83. 10.1016/S0140-6736(05)67702-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(05)67702-1</ArticleId><ArticleId IdType="pubmed">16298214</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye W, Ding X, Putnam N, et al. . Development of clinical prediction models for renal and cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease using time-varying predictors. J Diabetes Complications 2022;36:S1056-8727(22)00074-5. 10.1016/j.jdiacomp.2022.108180</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdiacomp.2022.108180</ArticleId><ArticleId IdType="pubmed">35339377</ArticleId></ArticleIdList></Reference><Reference><Citation>Lage MJ, Boye KS, Bae JP, et al. . The association between the severity of chronic kidney disease and medical costs among patients with type 2 diabetes. J Med Econ 2019;22:447&#x2013;54.:22. 10.1080/13696998.2019.1581208</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13696998.2019.1581208</ArticleId><ArticleId IdType="pubmed">30736708</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurray JJV, Packer M, Desai AS, et al. . Angiotensin-Neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993&#x2013;1004. 10.1056/NEJMoa1409077</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1409077</ArticleId><ArticleId IdType="pubmed">25176015</ArticleId></ArticleIdList></Reference><Reference><Citation>Heerspink HJL, Stef&#xe1;nsson BV, Correa-Rotter R, et al. . Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436&#x2013;46. 10.1056/NEJMoa2024816</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2024816</ArticleId><ArticleId IdType="pubmed">32970396</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiviott SD, Raz I, Sabatine MS. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. reply. N Engl J Med 2019;380:1881&#x2013;2. 10.1056/NEJMc1902837</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1902837</ArticleId><ArticleId IdType="pubmed">31067395</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurray JJV, Solomon SD, Inzucchi SE, et al. . Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995&#x2013;2008. 10.1056/NEJMoa1911303</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1911303</ArticleId><ArticleId IdType="pubmed">31535829</ArticleId></ArticleIdList></Reference><Reference><Citation>de Galan BE, Perkovic V, Ninomiya T, et al. . Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009;20:883&#x2013;92. 10.1681/ASN.2008070667</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2008070667</ArticleId><ArticleId IdType="pmc">PMC2663832</ArticleId><ArticleId IdType="pubmed">19225038</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahit MC, Kochar A, Granger CB. Post-myocardial infarction heart failure. JACC Heart Fail 2018;6:179&#x2013;86. 10.1016/j.jchf.2017.09.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2017.09.015</ArticleId><ArticleId IdType="pubmed">29496021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Yank V, Xiao L, et al. . Translating the diabetes prevention program lifestyle intervention for weight loss into primary care: a randomized trial. JAMA Intern Med 2013;173:113. 10.1001/2013.jamainternmed.987</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/2013.jamainternmed.987</ArticleId><ArticleId IdType="pmc">PMC3856315</ArticleId><ArticleId IdType="pubmed">23229846</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee A, Pasea L, Chung S-C, et al. . A population-based study of 92 clinically recognized risk factors for heart failure: Co-occurrence, prognosis and preventive potential. Eur J Heart Fail 2022;24:466&#x2013;80. 10.1002/ejhf.2417</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.2417</ArticleId><ArticleId IdType="pmc">PMC9305958</ArticleId><ArticleId IdType="pubmed">34969173</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lusignan S, Liaw S-T, Dedman D, et al. . An algorithm to improve diagnostic accuracy in diabetes in computerised problem orientated medical records (POMR) compared with an established algorithm developed in episode orientated records (EOMR). J Innov Health Inform 2015;22:255&#x2013;64. 10.14236/jhi.v22i2.79</Citation><ArticleIdList><ArticleId IdType="doi">10.14236/jhi.v22i2.79</ArticleId><ArticleId IdType="pubmed">26245239</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>